![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
|
Contact: Michael E. Newman
michael.newman@nist.gov
301-975-3025
National Institute of Standards and Technology (NIST)
Caption: Immunohistochemical detection of HER2 cancer biomarker with IgY antibody and quantum dots is demonstrated in these samples of breast cancer cells from a patient with normal HER2 expression (top) and one with over production (bottom). Cell nuclei are stained blue, quantum dots responding to the HER2 protein light up in bright red at the cell membranes. Treatment with trastuzumab could only be effective for the latter patient.
Credit: NIST
Usage Restrictions: None
Related news release: NIST, NCI, SAIC partner on new method for detecting HER2 breast cancer
|